Search Results - "Ung, Mony"

Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung by Ung, Mony, Rouquette, Isabelle, Filleron, Thomas, Taillandy, Kristell, Brouchet, Laurent, Bennouna, Jaafar, Delord, Jean-Pierre, Milia, Julie, Mazières, Julien

“…Micro-Abstract Sarcomatoid carcinoma is a rare subtype of lung cancer. We analyzed the clinicopathologic data from 93 patients treated at 2 institutions. The…”
Get full text

Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes by Glemarec, Gauthier, Lacaze, Jean-Louis, Cabarrou, Bastien, Aziza, Richard, Jouve, Eva, Zerdoud, Slimane, De Maio, Eleonora, Massabeau, Carole, Loo, Maxime, Esteyrie, Vincent, Ung, Mony, Dalenc, Florence, Izar, Francoise, Chira, Ciprian

“…Local ablative treatment (LAT) is increasingly combined with systemic therapy in oligometastatic breast cancer (OMBC), without a high-level evidence to support…”
Get full text

Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines by Maillard, Maud, Eche-Gass, Audrey, Ung, Mony, Brice, Aurélie, Marsili, Sabrina, Montastruc, Marion, Puisset, Florent, Thomas, Fabienne

“…We report the case of a 44-year-old patient who experienced severe toxicity while being treated with capecitabine at standard dose for metastatic breast…”
Get full text

Erratum to ‘Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes’ [The Breast (2023) 102–109] by Glemarec, Gauthier, Lacaze, Jean-Louis, Cabarrou, Bastien, Aziza, Richard, Jouve, Eva, Zerdoud, Slimane, De Maio, Eleonora, Massabeau, Carole, Loo, Maxime, Esteyrie, Vincent, Ung, Mony, Dalenc, Florence, Izar, Francoise, Chira, Ciprian

Get full text

Diagnosis, biology and epidemiology of oligometastatic breast cancer by Lacaze, Jean-Louis, Aziza, Richard, Chira, Ciprian, De Maio, Eleonora, Izar, Françoise, Jouve, Eva, Massabeau, Carole, Pradines, Anne, Selmes, Gabrielle, Ung, Mony, Zerdoud, Slimane, Dalenc, Florence

“…Does oligometastatic breast cancer (OMBC) deserve a dedicated treatment? Although some authors recommend multidisciplinary management of OMBC with a curative…”
Get full text

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database by Annonay, Mylène, Gauquelin, Lisa, Geiss, Romain, Ung, Mony, Cristol-Dalstein, Laurence, Mouret-Reynier, Marie-Ange, Goncalves, Anthony, Abadie-Lacourtoisie, Sophie, Francois, Eric, Perrin, Christophe, Le Fel, Johan, Lorgis, Véronique, Servent, Véronique, Uwer, Lionel, Jouannaud, Christelle, Leheurteur, Marianne, Joly, Florence, Campion, Loic, Courtinard, Coralie, Villacroux, Olivier, Petit, Thierry, Soubeyran, Pierre, Terret, Catherine, Bellera, Carine, Brain, Etienne, Delaloge, Suzette

“…Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work…”
Get full text

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME) by Sirieix, Junien, Fraisse, Julien, Mathoulin-Pelissier, Simone, Leheurteur, Marianne, Vanlemmens, Laurence, Jouannaud, Christelle, Diéras, Véronique, Lévy, Christelle, Ung, Mony, Mouret-Reynier, Marie-Ange, Petit, Thierry, Coudert, Bruno, Brain, Etienne, Pistilli, Barbara, Ferrero, Jean-Marc, Goncalves, Anthony, Uwer, Lionel, Patsouris, Anne, Tredan, Olivier, Courtinard, Coralie, Gourgou, Sophie, Frénel, Jean-Sébastien

“…Background and Aims: Because of its low prevalence, metastatic breast cancer (MBC) in males is managed based on clinical experience with women. Using a…”
Get full text

Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma by Vieira, Thibault, Girard, Nicolas, Ung, Mony, Monnet, Isabelle, Cazes, Aurélie, Bonnette, Pierre, Duruisseaux, Michael, Mazieres, Julien, Antoine, Martine, Cadranel, Jacques, Wislez, Marie

“…Sarcomatoid carcinomas (SCs) are rare tumors that may arise in the lung, accounting for 0.4% of non-small-cell lung cancers; the prognosis is poor. Only few…”
Get more information

Prognostic factors in hormone receptor positive oligometastatic breast cancer by Jean Louis, Lacaze, Cabarrou, Bastien, Glemarec, Gauthier, Brac de la Perrière, Clémence, Cassou Mounat, Thibaut, Chira, Ciprian, De Maio, Eleonora, Jouve, Eva, Massabeau, Carole, Nicolai, Vincent, Ung, Mony, Dalenc, Florence

“…1058 Background: Some recommend curative treatment for oligometastatic breast cancer (OMBC). To date, no randomized clinical trial has demonstrated the…”
Get full text

Abstract P1-20-18: Second axillary lymphadenectomy in case of ipsilateral breast cancer recurrence by Selmes, Gabrielle, Bachelier, Marine, Hessas, Miassa, Vaysse, Charlotte, De Maio, Eleonora, Lacaze, Jean-Louis, Ung, Mony, Jouve, Eva, Dalenc, Florence

“…Abstract Background: In case of ipsilateral recurrence, the interest of a new surgery is sure but the interest of a new axillary surgery is not established. A…”
Get full text

Investigating the clinical impact of dose‐banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study by Puisset, Florent, Le Louedec, Félicien, Dalenc, Florence, Verguet, Lorène, De Maio, Eleonora, Lacaze, Jean Louis, Montastruc, Marion, Ung, Mony, Vinson, Camille, Perriat, Sophie, Pacher, Sandrine, Chatelut, Etienne, Koning, Mélanie White

“…Aims Dose‐banding (DB) consists in approximating the theoretical dose of anticancer drugs calculated according to the body surface area (Dose‐BSA) of patients…”
Get full text

Abstract P1-18-09: Impact of prior adjuvant trastuzumab (aT) on clinical characteristics, patterns of recurrence and outcomes in 4145 patients with Her2 positive (HER2+) metastatic breast cancer (MBC)- Results from the French ESME UNICANCER program by Du, Fanny Le, Carton, Matthieu, Saghatchian, Mahasti, Perol, David, Pistilli, Barbara, Brain, Etienne, Loirat, Delphine, Vanlemmens, Laurence, Vermeulin, Thomas, Levy, Christelle, Goncalves, Anthony, Ung, Mony, Robert, Marie, Jaffre, Anne, Robain, Mathieu, Delaloge, Suzette, Dieras, Véronique

“…Abstract Background: The management of HER2+ BC has changed dramatically with the introduction and widespread use of HER2-targeted therapies, especially in the…”
Get full text

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program by Le Du, Fanny, Carton, Matthieu, Bachelot, Thomas, Saghatchian, Mahasti, Pistilli, Barbara, Brain, Etienne, Loirat, Delphine, Vanlemmens, Laurence, Vermeulin, Thomas, Emile, George, Gonçalves, Anthony, Ung, Mony, Robert, Marie, Jaffre, Anne, Desmoulins, Isabelle, Jouannaud, Christelle, Uwer, Lionel, Marc Ferrero, Jean, Mouret-Reynier, Marie-Ange, Jacot, William, Chevrot, Michaël, Delaloge, Suzette, Diéras, Véronique

“…Abstract Background Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as…”
Get full text

Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates by Dalenc, Florence, Sarradin, Victor, Nicolaï, Vincent, Franchet, Camille, Ung, Mony

“…Compared with other breast cancer subtypes, patients with metastatic triple-negative breast cancer (TNBC) are younger and have a worst overall survival with a…”
Get more information

Are neglected breast cancer relates to lifestyle and socioeconomic environment? by Farcy, Anne-lise, Jean Louis, Lacaze, Vaysse, Charlotte, Delpierre, Cyrille, Selmes, Gabrielle, Ung, Mony, BRAC de la PERRIERE, Clemence, Domenech, Carole, De Maio, Eleonora, Cabarrou, Bastien, Tremollieres, Florence, Dalenc, Florence

“…Abstract only e18542 Background: The incidence of patients with neglected breast cancer (NBC) in high-income countries remains an issue. It may be important to…”
Get full text

Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution by Lacaze, Jean-Louis, Chira, Ciprian, Glemarec, Gauthier, Monselet, Nils, Cassou-Mounat, Thibaut, De Maio, Eleonora, Jouve, Eva, Massabeau, Carole, Brac de la Perrière, Clémence, Selmes, Gabrielle, Ung, Mony, Nicolai, Vincent, Cabarrou, Bastien, Dalenc, Florence

“…Purpose Data about incidence, biological, and clinical characteristics of oligometastatic breast cancer (OMBC) are scarce. However, these data are essential in…”
Get full text

Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort by Carausu, Marcela, Carton, Matthieu, Dieras, Veronique C, Petit, Thierry, Guiu Lahaye, Severine, Veyret, Corinne, Goncalves, Anthony, Augereau, Paule, Ferrero, Jean-Marc, Levy, Christelle, Ung, Mony, Desmoulins, Isabelle, Debled, Marc, Bachelot, Thomas, Eymard, Jean-Christophe, Pistilli, Barbara, Frenel, Jean-Sebastien, Chevrot, Michaël, Mailliez, Audrey, Cabel, Luc

“…1043 Background: The place of endocrine therapy (ET) in the treatment of hormone receptor-positive (HR+), HER2+ metastatic breast cancer (MBC) is still not…”
Get full text

Abstract P1-18-19: Long term results with everolimus in advanced hormone receptor positive breast cancer in a multicenter national real world observational study (ESME) by Francois-Martin, Hélène, Lardy-Cleaud, Audrey, Pistilli, Barbara, Levy, Christelle, Diéras, Véronique, Frenel, Jean-Sébastien, Guiu, Séverine, Mouret-Reynier, Marie-Ange, Mailliez, Audrey, Eymard, Jean-Christophe, Petit, Thierry, Ung, Mony, Desmoulins, Isabelle, Augereau, Paule, Bachelot, Thomas, Uwer, Lionel, Debled, Marc, Ferrero, Jean-Marc, Veyret, Corinne, Goncalves, Antony, Chevrot, Michael, Cottu, Paul H

“…Abstract Background The everolimus (EVE)-exemestane combination has been included in the International guidelines for metastatic HR+/HER2- breast cancer (mBC)…”
Get full text

Abstract P2-18-06: Value of PAM50 risk of recurrence score in patients with HR positive HER2 negative early breast cancer and intermediate risk: A single cancer center institution prospective observational study by Nicolaï, Vincent, Gilhodes, Julia, Lacaze, Jean Louis, Ung, Mony, De Maio, Eleonora, Duprez-Paumier, Raphaelle, Vaysse, Charlotte, Filleron, Thomas, Jouve, Eva, Selmes, Gabrielles, Franchet, Camille, Massabeau, Carole, Chira, Cyprian, Izar, Francoise, Roché, Henri, Pradines, Anne, Dalenc, Florence

“…Abstract Background: Currently, clinico-pathological characteristics (CPC) such as tumor size, lymph node status, tumor grade, proliferation, lympho-vascular…”
Get full text

Abstract P1-19-19: Treatments and outcome in older versus younger women with HER2-positive metastatic breast cancer in the multicenter national observational ESME database by Annonay, Mylène, Abiven, Morgane, Brain, Etienne, Ung, Mony, Cristol-Dalstein, Laurence, Mouret-Reynier, Marie-Ange, Goncalves, Anthony, Abadie-Lacourtoisie, Sophie, Francois, Eric, Lefeuvre-Plesse, Claudia, Fel, Johann Le, Lorgis, Veronique, Servent, Veronique, Uwer, Lionel, Jouannaud, Christelle, Leheurteur, Marianne, Campion, Loic, Courtinard, Coralie, Villacroux, Olivier, Petit, Thierry, Soubeyran, Pierre, Bachelot, Thomas, Bellera, Carine, Delaloge, Suzette

“…Abstract Background: Prognosis of women with HER2+ metastatic breast cancer (MBC) has radically improved over the past 10 years, resulting from the…”
Get full text